dilazep has been researched along with Proteinuria in 10 studies
Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present study was to compare the effects of imidapril hydrochloride, an angiotensin converting enzyme inhibitor, and dilazep hydrochloride, an antiplatelet agent, on urinary protein excretion and renal function in patients with chronic glomerulonephritis." | 7.73 | Long-term effect of imidapril hydrochloride compared with dilazep hydrochloride administration on blood pressure and renal function in patients with chronic glomerulonephritis. ( Hayakawa, H; Hirata, Y; Kamijo, A; Kimura, K; Nagata, D; Nishimatsu, H; Oba, S; Satonaka, H; Suzuki, E; Takahashi, M; Takeda, R; Yamamoto, Y, 2005) |
| "The objective of the present study was to compare the effects of imidapril hydrochloride, an angiotensin converting enzyme inhibitor, and dilazep hydrochloride, an antiplatelet agent, on urinary protein excretion and renal function in patients with chronic glomerulonephritis." | 3.73 | Long-term effect of imidapril hydrochloride compared with dilazep hydrochloride administration on blood pressure and renal function in patients with chronic glomerulonephritis. ( Hayakawa, H; Hirata, Y; Kamijo, A; Kimura, K; Nagata, D; Nishimatsu, H; Oba, S; Satonaka, H; Suzuki, E; Takahashi, M; Takeda, R; Yamamoto, Y, 2005) |
| " Group I (early-treatment group, n = 10) was orally treated with 300 mg/kg body weight of this drug from 12 weeks of age until 60 weeks of age, and group II (late-treatment group, n = 10) was also treated with the same dosage of this drug from 20 weeks of age until 60 weeks of age." | 1.31 | Effect of dilazep hydrochlorideon the Im munohistopathology of IgA nephropathy in ddY mice. ( Hayashi, T; Kaneko, S; Shirato, I; Shou, I; Thang, NT; Tomino, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, T | 1 |
| Hirokawa, K | 1 |
| Matsuda, T | 1 |
| Osada, S | 1 |
| Takahashi, Y | 1 |
| Shimada, N | 1 |
| Koide, H | 1 |
| Fukuda, M | 1 |
| Morozumi, K | 2 |
| Oikawa, T | 1 |
| Motokawa, M | 1 |
| Usami, T | 1 |
| Yoshida, A | 2 |
| Kimura, G | 1 |
| Satonaka, H | 1 |
| Suzuki, E | 1 |
| Hayakawa, H | 1 |
| Nishimatsu, H | 1 |
| Nagata, D | 1 |
| Oba, S | 1 |
| Kamijo, A | 1 |
| Takeda, R | 1 |
| Takahashi, M | 1 |
| Yamamoto, Y | 1 |
| Kimura, K | 1 |
| Hirata, Y | 1 |
| Taji, Y | 1 |
| Kuwahara, T | 2 |
| Shikata, S | 1 |
| Morimoto, T | 1 |
| Sohmiya, S | 1 |
| Kobayashi, M | 1 |
| Sato, M | 1 |
| Fujinami, T | 1 |
| Gotoh, I | 1 |
| Yoshida, H | 1 |
| Kanatsu, K | 1 |
| Muso, E | 1 |
| Sekita, K | 1 |
| Ono, T | 1 |
| Konishi, N | 1 |
| Kanda, C | 1 |
| Minakata, T | 1 |
| Morimoto, K | 1 |
| Morikawa, A | 1 |
| Eto, M | 1 |
| Makino, I | 1 |
| Yamamoto, M | 1 |
| Fukui, M | 1 |
| Kuramoto, T | 1 |
| Kabuki, K | 1 |
| Tomino, Y | 2 |
| Hayashi, T | 1 |
| Kaneko, S | 1 |
| Thang, NT | 1 |
| Shou, I | 1 |
| Shirato, I | 1 |
| Inage, H | 1 |
| Koyama, A | 1 |
| Narita, M | 1 |
| Tojo, S | 1 |
2 reviews available for dilazep and Proteinuria
| Article | Year |
|---|---|
Immunotactoid glomerulopathy with microtubular deposits, with reference to the characteristics of Japanese cases.
Topics: Aged; Alprostadil; Biopsy, Needle; Blood Chemical Analysis; Blood Transfusion; Combined Modality The | 2005 |
Meta-analysis of antiplatelet therapy for IgA nephropathy.
Topics: Dilazep; Dipyridamole; Glomerulonephritis, IGA; Humans; Kidney Function Tests; Platelet Aggregation | 2006 |
8 other studies available for dilazep and Proteinuria
| Article | Year |
|---|---|
Combination AST-120 and dilazep dihydrochloride therapy reduced urinary protein excretion and serum creatinine levels in patients with chronic renal failure.
Topics: Aged; Carbon; Creatinine; Dilazep; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chroni | 2002 |
Long-term effect of imidapril hydrochloride compared with dilazep hydrochloride administration on blood pressure and renal function in patients with chronic glomerulonephritis.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Dilazep; Drug Ther | 2005 |
[Clinical effects of dilazep dihydrochloride on glomerulonephritis].
Topics: Adult; Aged; Azepines; Chronic Disease; Dilazep; Female; Glomerulonephritis; Hematuria; Humans; Male | 1983 |
Effects of an anti-platelet drug (dilazep) in IgA nephropathy: comparison of clinical effects with renal biopsy findings.
Topics: Adult; Biopsy; Dilazep; Female; Glomerulonephritis, IGA; Humans; Immunoglobulins; Kidney; Male; Prot | 1994 |
The effect of dilazep on urinary protein excretion in spontaneous diabetic Chinese hamster.
Topics: Animals; Basement Membrane; Cricetinae; Cricetulus; Diabetes Mellitus, Experimental; Diabetic Nephro | 1993 |
Effects of antiplatelet drug dilazep dihydrochloride on anionic sites and extracellular matrix (ECM) components in glomerular basement membrane of STZ-induced diabetic rats.
Topics: Animals; Anions; Basement Membrane; Binding Sites; Creatinine; Diabetes Mellitus, Experimental; Diab | 1995 |
Effect of dilazep hydrochlorideon the Im munohistopathology of IgA nephropathy in ddY mice.
Topics: Animals; Collagen; Dilazep; Female; Fibronectins; Fluorescent Antibody Technique; Glomerular Mesangi | 2000 |
Effects of the antiplatelet agents, dipyridamole and dilazep dihydrochloride, on in vivo platelet function and proteinuria.
Topics: Adolescent; Adult; Azepines; Blood Platelets; Dilazep; Dipyridamole; Female; Humans; Male; Middle Ag | 1985 |